ILE Isolagen

EXTON, Pa., Jan. 3 /PRNewswire-FirstCall/ -- Isolagen, Inc. (AMEX:ILE) announced today that Nicholas L. Teti, Jr., Chairman and Chief Executive Officer of Isolagen, will present at the 25th Annual JPMorgan Healthcare Conference on Wednesday, January 10th, 2007 at 10am PST at the Westin St. Francis in San Francisco. The presentation will be webcast within 24 hours and can be accessed on the investor page of the Isolagen website, http://www.isolagen.com/. The webcast will be archived on the company's website for 90 days. About Isolagen, Inc. Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company's product candidates are based on its proprietary Isolagen Process. Autologous cellular therapy is the process whereby a patient's own cells are extracted, allowed to multiply and then injected into the patient. Isolagen's product candidates are designed to be minimally invasive and non-surgical. For additional information, please visit: http://www.isolagen.com/. All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2005, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2005, as well as other public filings with the SEC since such date. DATASOURCE: Isolagen, Inc. CONTACT: Investors: Charles Huiner of Isolagen, +1-484-713-6200, or ; or Media: Mike Beyer of Sam Brown Inc., +1-773-463-4211, or , for Isolagen Web site: http://www.isolagen.com/

Copyright